CompanyGraph
Wuhan Easydiagnosis Biomedicine Co., Ltd.
002932 · SZSE · China
mdeasydiagnosis.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionCurrent ratio is 18.35×, higher than 95% of its Medical Devices peers (median 3.83×)
- FinancialsAltman Z-Score 8.43: safe zone
- Interpretations5 currently firing — 5
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.56BCNY528.03M · vs all stocks (USD)
Revenue (TTM)
265.79MCNY39.47M · vs all stocks (USD)
Profit Margin
-4.96%vs Medical Devices peers
Beta
0.3500xvs all stocks
52-Week Change
-28.11%vs all stocks
Market Capitalization
3.56BCNY528.03M · vs all stocks (USD)
Enterprise Value
684.80MCNY101.71M · vs all stocks (USD)
Price to Sales (TTM)
13.26xvs Medical Devices peers
Price to Book (MRQ)
0.6019xvs Medical Devices peers
Enterprise to Revenue
2.58xvs Medical Devices peers
Enterprise to EBITDA
-5.02xvs Medical Devices peers
Gross Margin
50.30%vs Medical Devices peers
Profit Margin
-4.96%vs Medical Devices peers
Operating Margin
-18.22%vs Medical Devices peers
Return on Assets (TTM)
-1.87%vs Medical Devices peers
Return on Equity (TTM)
-1.20%vs Medical Devices peers
Revenue (TTM)
265.79MCNY39.47M · vs all stocks (USD)
Revenue per Share (TTM)
1.21CNYUpdated Aug 20, 2026Quarterly Revenue Growth
1.00%vs Medical Devices peers
Gross Profit (TTM)
110.25MCNY16.37M · vs all stocks (USD)
EBITDA (TTM)
69.36MCNY10.30M · vs all stocks (USD)
Net Income (TTM)
-13.18MCNY-1.96M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-43.21%vs Medical Devices peers
Operating Cash Flow (TTM)
-66.29MCNY-9.85M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-1.06BCNY-157.57M · vs all stocks (USD)
5-Year Average Dividend Yield
7.46%vs all stocks
Payout Ratio
2956.73%vs Medical Devices peers
Minority Interest (Equity)
127.33MCNYFY2025 · Dec 31, 2025Revenue
265.08MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
169.21MCNYFY2025 · Dec 31, 2025Gross Profit
95.87MCNYFY2025 · Dec 31, 2025Operating Income
-105.95MCNY-15.74M · vs all stocks (USD)
Pre-tax Income
-63.79MCNYFY2025 · Dec 31, 2025Income Tax Expense
11.27MCNYFY2025 · Dec 31, 2025Net Income
-75.06MCNYFY2025 · Dec 31, 2025EBIT
-63.34MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
69.36MCNYFY2025 · Dec 31, 2025Research & Development
85.78MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
53.05MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.09MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.49MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
458.65KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.0700CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.0700CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
235.15MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
235.15MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-75.06MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
58.60MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
146.24MCNYFY2025 · Dec 31, 2025Free Cash Flow
59.51MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
452.16MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-75.06MCNYFY2025 · Dec 31, 2025Other Non-cash Items
2.97MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
176.21MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
42.11MCNYFY2025 · Dec 31, 2025Capital Expenditures
-86.73MCNYFY2025 · Dec 31, 2025Net Acquisitions
844.64KCNYFY2025 · Dec 31, 2025Purchase of Investments
-795.19MCNYFY2025 · Dec 31, 2025Sale of Investments
1.31BCNYFY2025 · Dec 31, 2025Other Investing Activity
-1.22MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
429.91MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-3.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-263.26MCNYFY2025 · Dec 31, 2025Other Financing Charges
-17.11MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-283.37MCNYFY2025 · Dec 31, 2025Shares Outstanding
232.52MSharesUpdated Aug 20, 2026Float Shares
111.40MSharesUpdated Aug 20, 2026% Held by Insiders
50.55%vs all stocks
% Held by Institutions
5.77%vs all stocks
Total Cash (MRQ)
2.85BCNY423.53M · vs all stocks (USD)
Total Cash per Share (MRQ)
12.99CNYUpdated Aug 20, 2026Total Debt (MRQ)
24.26MCNY3.60M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0043xvs Medical Devices peers
Current Ratio (MRQ)
18.35xvs Medical Devices peers
Book Value per Share (MRQ)
25.19CNYUpdated Aug 20, 2026Total Assets
5.98BCNY888.20M · vs all stocks (USD)
Total Current Assets
4.68BCNYFY2025 · Dec 31, 2025Total Liabilities
324.56MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.30BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
83.58MCNYFY2025 · Dec 31, 2025Total Current Liabilities
240.99MCNYFY2025 · Dec 31, 2025Cash
490.15MCNYFY2025 · Dec 31, 2025Cash Equivalents
20.76MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
510.90MCNYFY2025 · Dec 31, 2025Other Short-term Investments
394.35MCNYFY2025 · Dec 31, 2025Accounts Receivable
466.40MCNYFY2025 · Dec 31, 2025Inventory
65.10MCNYFY2025 · Dec 31, 2025Accounts Payable
81.32MCNYFY2025 · Dec 31, 2025Short-term Debt
4.53MCNYFY2025 · Dec 31, 2025Other Current Liabilities
8.46MCNYFY2025 · Dec 31, 2025Long-term Debt
3.19MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
1.14MCNYFY2025 · Dec 31, 2025Common Stock (Book)
232.52MCNYFY2025 · Dec 31, 2025Retained Earnings
4.10BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.66BCNY839.99M · vs all stocks (USD)
Treasury Stock
247.96MCNYFY2025 · Dec 31, 202552-Week Low
13.67CNYUpdated Aug 20, 202652-Week High
21.83CNYUpdated Aug 20, 202652-Week Change
-28.11%vs all stocks
Beta
0.3500xvs all stocks
50-Day MA
14.67CNYUpdated Aug 20, 2026200-Day MA
17.17CNYUpdated Aug 20, 2026Avg 10-Day Volume
1.12MSharesUpdated Aug 20, 2026Avg 30-Day Volume
1.18MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-0.0500CNYUpdated Aug 20, 20265 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How is this stock valued?
Inverted P/B With Liquidity And Equity Ratio
It trades below book value, with current assets ample and the balance sheet equity-funded.
Reads
Where is this company structurally exposed?
Diagnostic
Declining With Price Stretched Below 1Y Mean
The price sits well below its yearly mean, with net income and assets falling four years.
Reads
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 18.35×, higher than 95% of its Medical Devices peers (median 3.83×)Significant
Current ratio: 18.35Industry median: 3.83Industry P95: 12.54Peers compared: 102
Price-to-book is 0.6×, lower than 95% of its Medical Devices peers (median 2.69×)Notable
Price-to-book: 0.60Industry median: 2.69Industry P5: 0.66Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.50Profit Margin: -0.05
Financial Health
Altman Z-Score 8.43: safe zoneNotable
Altman Z-Score: 8.43
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Jiangsu Bioperfectus Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Verastem Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Miracure Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Assembly Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Contineum Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai General Healthy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
IOL Chemicals and Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aim Vaccine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Nanjing Xinjiekou Department Store Co. Ltd.
4 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDown-Close Share With Multi-Year Earnings DecreaseLow-Leverage Liquidity ConfigurationInverted P/B With Liquidity And Equity Ratio
Heron Neutron Medical Corp.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDown-Close Share With Multi-Year Earnings DecreaseLow-Leverage Liquidity Configuration
Liaoning Chengda Biotechnology Co., Ltd.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityDown-Close Share With Multi-Year Earnings DecreaseLow-Leverage Liquidity Configuration